Table 1. Representative large studies of Lung PDX model development.
| Publication | Patients | Tissue collection | Mouse strain | Engraftment rate | Engrafted tumor histology [n] |
|---|---|---|---|---|---|
| Fichtner et al. (55) | NSCLC | Surgical resection | NOD/SCID | 25/102 (24.5%) | Adenocarcinoma [6] |
| Squamous [12] | |||||
| Others [7] | |||||
| Wang et al. (49) | NSCLC | Surgical resection | NOD/SCID | 127/441 (28.8%) | Adenocarcinoma [52] |
| Squamous [62] | |||||
| Others [13] | |||||
| Hao et al. (64) | NSCLC | Surgical resection | NOD/SCID | 23/88 (26.1%) | Adenocarcinoma [11] |
| Squamous [9] | |||||
| Others [3] | |||||
| John et al. (63) | NSCLC | Surgical resection | NOD/SCID | Adenocarcinoma 30/96 (31.1%) Squamous 29/45 (64.4%) |
Adenocarcinoma [30] |
| Squamous [29] | |||||
| Others [4] | |||||
| Nakajima et al. (60) | NSCLC& SCLC | EBUS-guided biopsy | NSG | Adenocarcinoma 3/12 (25%) | Adenocarcinoma [3] |
| Squamous 2/3 (66.7%) | Squamous [2] | ||||
| Small cell carcinoma 2/3 (66.7%) | Small cell carcinoma [2] | ||||
| Large cell carcinoma 1/1 (100%) | Large cell carcinoma [1] | ||||
| Fang et al. (65) | NSCLC& SCLC | Surgical resection | BALB/c nude mice | N/a | Adenocarcinoma [15] |
| Squamous [68] | |||||
| Others [16] | |||||
| Kang et al. (66) | NSCLC | Surgical resection & biopsy | NOD and nude | Adenocarcinoma 30/92 (32.6%) | Adenocarcinoma [30] |
| Squamous 11/30 (36.7%) | Squamous [11] | ||||
| Kita et al. (67) | NSCLC | Surgical resection | NSG & SHO | Adenocarcinoma 13/48 (27.1%) | Adenocarcinoma [13] |
| Squamous 6/10 (60%) | Squamous [6] | ||||
| Large cell carcinoma 1/2 (50%) | Large cell carcinoma [1] | ||||
| Cuenca et al. (68) | NSCLC | Surgical resection | SCID | Adenocarcinoma 9/28 (32.1%) | Adenocarcinoma [9] |
| Squamous 6/19 (31.5%) | Squamous [6] | ||||
| Adenosquamous [1] | |||||
| Drapkin et al. (56) | SCLC | CTC | NSG | 16/42 (38.1%) | Small cell carcinoma [16] |
| Hodgkinson et al. (69) | SCLC | CTC | NSG | 4/6 (66.7%) | Small cell carcinoma [4] |
NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; CTC, circulating tumor cell; NOD, nonobese diabetic; SCID, severely compromised immune deficient; NSG, NOD-SCID gamma.